Background: This reserach aimed to determine the correlation between the morphology index and IgM anti PGL-1, and the mutations in gyrA genes in order to detect ofloxacin resistance in the patients with multibacillary (MB) leprosy. Methods: This research was conducted in Dr. Wahidin Sudirohusodo General Hospital and its network hospitals in Makassar using the cohort retrospective design. The research sample comprised 21 patients with MB leprosy who had completed the ROM treatment regimens, and whose bacterial index (BI), morphology index (MI), IgM anti PGL-1 antibody, PCR, and sequencing, skin lesion number, and treatment regularity had been examined. Result: The research revealed that all the samples did not undergo any mutations of the gyrA genes which was responsible for the ofloxacin resistance; however, there was a correlation between BI and the IgM anti PGL-1 antibody, and between IgM anti PGL-1 antibody and the number of the skin lesions. Conclusions: There was no samples found to undergo the mutations of gyrA genes, this could be used as the reference to assess the correlation between the morphology index and the IgM anti PGL-1 antibody with the mutations of the gyrA genes.
Published in | American Journal of Clinical and Experimental Medicine (Volume 3, Issue 4) |
DOI | 10.11648/j.ajcem.20150304.17 |
Page(s) | 167-171 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
gyrA Genes, Morphology Index, IgM Anti PGL-1 Antibody, Ofloxacin Resistance
[1] | Amiruddin, M.D., Hakim, Z., Darwis, E. Diagnosis Penyakit Kusta. In: Sjamsoe-Daili, E.S., Menaldi, S.L., Ismiarto, S.P., Nilasari, H., eds. Kusta. 2003. Balai Penerbit FKUI: Jakarta. |
[2] | World Health Organization. Chemotherapy of Leprosy for Control Programmes. Report of a WHO Study Group. WHO Technical Report Series 675. 1982. Wordl Health Organization, Genewa, Switzerland. |
[3] | Williams, D.L., Spring, L., Harris, E. Dihydropteroate Synthase of Mycobacterium leprae and Dapsone Resistance. Antimicrob Agents Chemother. 2000; 44: 1530-7. |
[4] | Setia, M.S., Shinde, S.S., Jerajani, H.R., Boivin, J.S. Is There a Role for Rifampicin, Ofloxacin, and Minocycline (ROM) Therapy in the Treatment of Leprosy? Systematic Review and Meta-Analysis. Trop Med & Intern Health. 2011; 16: 1541-51. |
[5] | Cambau, E., Perani, E., Guilemin, I., Jamet, P., Ji, B. Multidrug-Resistance to Dapson, Rifampicin, and Ofloxacin in Mycobacterium Leprae. The Lancet. 1997; 349: 103-4. |
[6] | Bryceson, A. and Pfaltzgraff E.R., eds. Leprosy.1990. Churchill Livingstone: London. |
[7] | Agusni, I. Imunologi penyakit kusta. In: Sudigdoadi, Sutedja, E., Agusni, I., Sugiri, U., eds. Makalah Lengkap Kursus Imuno-Dermatologi II Dokter Spesialis Kulit dan Kelamin. Bandung: SMF I.K.Kulit & Kelamin RS Hasan Sadikin. 2000; 231-44. |
[8] | World Health Organization. 2009. Guidelines for Global Surveillance of Drug Resistance in Leprosy. 2009. World Health Organization: New Delhi. |
[9] | Noordeen, S. Epidemiology of Leprosy. In: Hastings, R.C. and Opromella, D.V.A., eds. Leprosy. 1994. Churchil Livingstone: New York. |
[10] | Assiri, A., Yezli, S., Tayeb, T., Almasri, M., Bamgboye, A.E., Memish, Z.A. Eradicating Leprosy in Saudi Arabia: Outcome of a Ten-Year Surveillance (2003-2012). TMAID. 2014; 12: 771-7. |
[11] | Weiand, D., Thoulass, J., Smith, W.C.S. Assessing and Improving Adherence with Multidrug Therapy. Lepr Rev. 2012; 83: 282-91. |
[12] | Haryanto, S., Mardini., Pratiwi, Y.S., Pamungkas, I.Y. 2011. Compliance With Type MB Leprosy Patients Post- Treatment Multi Drug Therapy (MDT) With Laboratory Test Results Mycobacterium Leprae In Health Care District Blora. J Ilmu Keperawatan Indonesia. 2011; 1: 1-9. |
[13] | Villahermosa, L.G., Fajardo, T.T., Abalos, R.M., Cellona, R.V., Balagon, M.V., Cruz, E.C.D., Tan, E.V. Parallel Assasment of 24 Monthly Doses of Rifampicin, Ofloxacin, and Minocycline Versus Two Years of World Health Organization Multi-Drug Therapy for Multi-Bacillary Leprosy. Am J Trop Med Hyg. 2004; 75(2): 197-200. |
[14] | Zenha, E.M.R., Ferreira, M.A.N., Foss N.T. Use of Anti-PGL-1 Antibodies to Monitor Therapy Regimens in Leprosy Patients. 2009; 42: 968-72. |
[15] | Lyon, S., Silva, S., Lyon, A.C., Grossi, M.A., Azevedo, M.L., Buhrer-Sekula, S., Rocha, M.O. Association of the ML Flow Serological Test with Slit Skin Smear. Revista da Sociedade Brasileira de Med Trop. 2008; 41: 23-6. |
[16] | De Moura, R.S., Calado, K.L., Oliveira, M.L., Buhrer-Sekula, S. Leprosy Serology Using PGL-1: A Sistemic Review. Revista da Sociedade Brasileira de Med Trop. 2008; 41: 11-8. |
[17] | Agusni, I., Menaldi, S.L. Beberapa Prosedur Diagnostik Baru pada Penyakit Kusta. In: Sjamsoe-Daili, E.S., Menaldi, S.L., Ismiarto, S.P., Nilasari, H, eds. Kusta. 2003. Balai Penerbit FKUI : Jakarta. |
[18] | Matsuoka, M., Budiawan, T., Aye, K.S., Kyaw, K., Tan, E.V., Cruz, E.D., Gelber, R., Saunderson, P., Balagon, V., Pannikar, V. The Frequency of Drug Resistance Mutations in M.Leprae Isolates in Untreated and Relapsed Leprosy Patients from Myanmar, Indonesia and the Philippines. Lepr Rev. 2007; 78: 343-52. |
[19] | Kai, M., Phuc, N.H.N., Nguyen, H.A., Pham,T.H.B.D., Nguyen, N.H., Miyamoto, Y., et al. Analysis of Drug-Resistant Strains of Mycobacterium leprae in an Endemic Area of Vietnam. CID. 2011; 52: e127-32. |
[20] | Matsuoka, M. Drug Resistance in Leprosy. Jpn J Infect Dis. 2010; 63: 1-7. |
[21] | Cambau, E., Bonnafous, P., Perani, E., Sougakoff, W., Ji, B., Jarlier, V. Molecular Detection of Rifampin and Ofloxacin Resistance for Patients Who Experience Relapse of Multibacillary Leprosy. Clinical Infect Dis. 2002; 34: 39-45. |
APA Style
Arif Risdianto Karim, Muh Dali Amiruddin, Farida Tabri, R. Satriono, Mochammad Hatta, et al. (2015). The Analysis of the Mycobacterium Leprae Resistance Against Ofloxacin After the Rifampicin Ofloxacin Minocycline (ROM) Therapy. American Journal of Clinical and Experimental Medicine, 3(4), 167-171. https://doi.org/10.11648/j.ajcem.20150304.17
ACS Style
Arif Risdianto Karim; Muh Dali Amiruddin; Farida Tabri; R. Satriono; Mochammad Hatta, et al. The Analysis of the Mycobacterium Leprae Resistance Against Ofloxacin After the Rifampicin Ofloxacin Minocycline (ROM) Therapy. Am. J. Clin. Exp. Med. 2015, 3(4), 167-171. doi: 10.11648/j.ajcem.20150304.17
AMA Style
Arif Risdianto Karim, Muh Dali Amiruddin, Farida Tabri, R. Satriono, Mochammad Hatta, et al. The Analysis of the Mycobacterium Leprae Resistance Against Ofloxacin After the Rifampicin Ofloxacin Minocycline (ROM) Therapy. Am J Clin Exp Med. 2015;3(4):167-171. doi: 10.11648/j.ajcem.20150304.17
@article{10.11648/j.ajcem.20150304.17, author = {Arif Risdianto Karim and Muh Dali Amiruddin and Farida Tabri and R. Satriono and Mochammad Hatta and Marianti Manggau}, title = {The Analysis of the Mycobacterium Leprae Resistance Against Ofloxacin After the Rifampicin Ofloxacin Minocycline (ROM) Therapy}, journal = {American Journal of Clinical and Experimental Medicine}, volume = {3}, number = {4}, pages = {167-171}, doi = {10.11648/j.ajcem.20150304.17}, url = {https://doi.org/10.11648/j.ajcem.20150304.17}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20150304.17}, abstract = {Background: This reserach aimed to determine the correlation between the morphology index and IgM anti PGL-1, and the mutations in gyrA genes in order to detect ofloxacin resistance in the patients with multibacillary (MB) leprosy. Methods: This research was conducted in Dr. Wahidin Sudirohusodo General Hospital and its network hospitals in Makassar using the cohort retrospective design. The research sample comprised 21 patients with MB leprosy who had completed the ROM treatment regimens, and whose bacterial index (BI), morphology index (MI), IgM anti PGL-1 antibody, PCR, and sequencing, skin lesion number, and treatment regularity had been examined. Result: The research revealed that all the samples did not undergo any mutations of the gyrA genes which was responsible for the ofloxacin resistance; however, there was a correlation between BI and the IgM anti PGL-1 antibody, and between IgM anti PGL-1 antibody and the number of the skin lesions. Conclusions: There was no samples found to undergo the mutations of gyrA genes, this could be used as the reference to assess the correlation between the morphology index and the IgM anti PGL-1 antibody with the mutations of the gyrA genes.}, year = {2015} }
TY - JOUR T1 - The Analysis of the Mycobacterium Leprae Resistance Against Ofloxacin After the Rifampicin Ofloxacin Minocycline (ROM) Therapy AU - Arif Risdianto Karim AU - Muh Dali Amiruddin AU - Farida Tabri AU - R. Satriono AU - Mochammad Hatta AU - Marianti Manggau Y1 - 2015/06/25 PY - 2015 N1 - https://doi.org/10.11648/j.ajcem.20150304.17 DO - 10.11648/j.ajcem.20150304.17 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 167 EP - 171 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20150304.17 AB - Background: This reserach aimed to determine the correlation between the morphology index and IgM anti PGL-1, and the mutations in gyrA genes in order to detect ofloxacin resistance in the patients with multibacillary (MB) leprosy. Methods: This research was conducted in Dr. Wahidin Sudirohusodo General Hospital and its network hospitals in Makassar using the cohort retrospective design. The research sample comprised 21 patients with MB leprosy who had completed the ROM treatment regimens, and whose bacterial index (BI), morphology index (MI), IgM anti PGL-1 antibody, PCR, and sequencing, skin lesion number, and treatment regularity had been examined. Result: The research revealed that all the samples did not undergo any mutations of the gyrA genes which was responsible for the ofloxacin resistance; however, there was a correlation between BI and the IgM anti PGL-1 antibody, and between IgM anti PGL-1 antibody and the number of the skin lesions. Conclusions: There was no samples found to undergo the mutations of gyrA genes, this could be used as the reference to assess the correlation between the morphology index and the IgM anti PGL-1 antibody with the mutations of the gyrA genes. VL - 3 IS - 4 ER -